Galmed Pharmaceuticals
GLMD
18 hedge funds and large institutions have $19.5M invested in Galmed Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
10% less funds holding
Funds holding: 20 → 18 (-2)
17% less capital invested
Capital invested by funds: $23.4M → $19.5M (-$3.95M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
California Public Employees Retirement System
Sacramento,
California
|
+$295K |
| 2 |
Renaissance Technologies
New York
|
+$280K |
| 3 |
Morgan Stanley
New York
|
+$115K |
| 4 |
II
Ibex Investors
Denver,
Colorado
|
+$35K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$505K |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$480K |
| 3 |
VC
Voss Capital
Houston,
Texas
|
-$443K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$310K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$254K |
GLMD Hedge Fund Activity: Q4 2020 in Review
18 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2020, worth a combined $19.5M — down 17% from $23.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of GLMD and 3 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was California Public Employees Retirement System, opening a new position worth an estimated $295K. The largest seller was Nantahala Capital Management, cutting an estimated $505K.
- 18 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2020, down from 20 in Q3 2020.
- Funds reported $19.5M of Galmed Pharmaceuticals stock for Q4 2020, down 17% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q4 2020 and 5 closed out, a net change of -2 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2020 was California Public Employees Retirement System, an estimated $295K added.
- The largest Galmed Pharmaceuticals seller in Q4 2020 was Nantahala Capital Management, an estimated $505K sold.
Based on aggregated 13F filings for Q4 2020.